Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Mar;52(3):994-7.
doi: 10.1128/JCM.03044-13. Epub 2014 Jan 8.

Impact of new antifungal breakpoints on antifungal resistance in Candida species

Annette W Fothergill  1 , Deanna A Sutton, Dora I McCarthy, Nathan P Wiederhold
Affiliations
Comparative Study

Impact of new antifungal breakpoints on antifungal resistance in Candida species

Annette W Fothergill et al. J Clin Microbiol. 2014 Mar.

Abstract

We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).

PubMed Disclaimer

Figures

FIG 1
FIG 1
Percentage of Candida isolates per species classified as resistant to anidulafungin (AFG), micafungin (MFG), fluconazole (FLU), and voriconazole (VOR) per the previous and recently revised CLSI antifungal clinical breakpoints (CBP).
See this image and copyright information in PMC

References

    1. CLSI 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA
    1. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommittee for Antifungal Susceptibility Testing 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180–195. 10.1016/j.drup.2010.09.002 - DOI - PubMed
    1. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Susceptibility Testing 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164–176. 10.1016/j.drup.2011.01.004 - DOI - PubMed
    1. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125:S3–S13. 10.1016/j.amjmed.2011.11.001 - DOI - PubMed
    1. CLSI 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA

Publication types

MeSH terms

Substances

LinkOut - more resources